1571111-72-2

Upstream product

• 90162-13-3 methyl 6-hydroxy-1-naphthoate 
• 2437-17-4 6-hydroxy-1-naphthoic acid 
• 1290056-68-6 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-naphthalene-1-carboxylic acid 
• 372-39-4 3,5-difluoroaniline 
• 919363-25-0 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-naphthalene-1-carboxylic acid methyl ester 
• 255050-65-8 6-trifluoromethanesulfonyloxy-naphthalene-1-carboxylic acid methyl ester 

Downstream Products

• 1571111-50-6 6-(3-amino-1H-indazol-4-yl)-N-(3,5-difluorophenyl)-1-naphthalenecarboxamide 

Relevant academic research and scientific papers

NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comp

Discovery of a new series of naphthamides as potent VEGFR-2 kinase inhibitors

Inhibition of VEGFR-2 signaling pathway has already become one of the most promising approaches for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of a new series of naphthamides as potent inhibitors of VEGFR-2. Among these compounds, 14c exhibited high VEGFR-2 inhibitory potency in both enzymatic and HUVEC cellular proliferation assays, with IC50 values of 1.5 and 0.9 nM, respectively. Kinase selectivity profiling revealed that 14c was a multitargeted inhibitor, and it also exhibited good potency against VEGFR-1, PDGFR-β, and RET. Furthermore, 14c effectively blocked tube formation of HUVEC at nanomolar level. Overall, 14c might be a promising candidate for the treatment of cancer.